{"id":"NCT02997202","sponsor":"Astellas Pharma Global Development, Inc.","briefTitle":"A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-16","primaryCompletion":"2023-01-07","completion":"2023-05-09","firstPosted":"2016-12-19","resultsPosted":"2024-09-19","lastUpdate":"2025-01-17"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"gilteritinib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Gilteritinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who underwent hematopoietic stem cell transplant (HCT) and were randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.","primaryOutcome":{"measure":"Relapse-free Survival (RFS)","timeFrame":"From the date of randomization up to 64 months and 22 days","effectByArm":[{"arm":"Gilteritinib","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0518"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":14},"locations":{"siteCount":118,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Greece","Italy","Japan","New Zealand","Poland","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40590852","39775763","39167766","38663769","38471061"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=14519&tenant=MT_AST_9011"]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":178},"commonTop":["Chronic graft versus host disease","Acute graft versus host disease","Nausea","Diarrhoea","Neutrophil count decreased"]}}